Lead party: Laprophan S.A (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Investor view in Meridian Capital
Target: Rivopharm SA (private company) · Sector: Healthcare, Biotechnology, Pharmaceuticals
Transaction type: Merger/Acquisition(M&A) · Asset class: Corporate Transactions · Strategy: Strategic Majority · Instrument: Ordinary Shares (Equity)
Lead investor/buyer: Laprophan S.A · Investors/buyers: Laprophan S.A
Legal advisers: not identified in the source record.
Source: announced 25 June 2026. Original announcement: mcapitalp.com.


